HENLIUS: VOLUNTARY ANNOUNCEMENT - APPLICATION FOR THE CLINICAL TRIAL OF HLX53 (ANTI-TIGIT FC FUSION PROTEIN) IN COMBINATION WITH HANSIZHUANG (SERPLULIMAB INJECTION) AND HANBEITAI (BEVACIZUMAB INJECTION) FOR THE FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC
Apr 17 04:56 ET
HENLIUS: FORM OF PROXY FOR THE 2024 FIRST CLASS MEETING OF DOMESTIC SHAREHOLDERS AND UNLISTED FOREIGN SHAREHOLDERS TO BE HELD ON MONDAY, 20 MAY 2024
Apr 17 04:40 ET
HENLIUS: FORM OF PROXY FOR THE 2024 FIRST CLASS MEETING OF H SHAREHOLDERS TO BE HELD ON MONDAY, 20 MAY 2024
Apr 17 04:39 ET
HENLIUS: PROXY FORM FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MONDAY, 20 MAY 2024 (OR ANY ADJOURNMENT THEREOF)
Apr 17 04:38 ET
HENLIUS: 2023 Environmental, Social and Governance Report
Apr 17 04:33 ET
HENLIUS: VOLUNTARY ANNOUNCEMENT - AN INTERNATIONAL MULTI-CENTRE PHASE 3 CLINICAL STUDY OF A BIOSIMILAR OF DENOSUMAB HLX14 (RECOMBINANT ANTI-RANKL HUMAN MONOCLONAL ANTIBODY INJECTION) FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT HIGH RISK FO
Apr 5 06:00 ET
HENLIUS: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
Apr 3 04:51 ET
HENLIUS: PROPOSED CHANGE OF REGISTERED ADDRESS IN CHINA AND PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
Mar 21 05:00 ET
HENLIUS: VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF HLX42 FOR INJECTION (ANTIBODY-DRUG CONJUGATE TARGETING EGFR WITH NOVEL DNA TOPOISOMERASE I INHIBITOR) FOR THE TREATMENT OF ADVANCE/METASTATIC SOLID TUMOURS IN
Mar 14 09:00 ET
HENLIUS: VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL OF HLX6018 WAS APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Mar 12 06:20 ET
HENLIUS: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
Mar 1 04:44 ET
HENLIUS: VOLUNTARY ANNOUNCEMENT - THE SUPPLEMENTAL APPLICATIONS OF HANDAYUAN (ADALIMUMAB INJECTION) FOR THE NEW INDICATIONS HAVE BEEN ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Feb 29 04:00 ET
HENLIUS: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
Feb 6 03:41 ET
HENLIUS: VOLUNTARY ANNOUNCEMENT - THE PHASE 1 CLINICAL STUDY OF A BIOSIMILAR OF DENOSUMAB HLX14 (RECOMBINANT ANTI-RANKL HUMAN MONOCLONAL ANTIBODY INJECTION) SUCCESSFULLY COMPLETED
Feb 1 03:50 ET
HENLIUS: Notification Letter and Reply Form to Non-Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
Jan 30 03:35 ET
HENLIUS: Notification Letter and Reply Form to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications
Jan 30 03:30 ET
HENLIUS: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
Jan 3 03:37 ET
HENLIUS: VOLUNTARY ANNOUNCEMENT - HANSIZHUANG (SERPLULIMAB INJECTION) HAS BEEN APPROVED FOR MARKETING IN INDONESIA FOR THE TREATMENT OF EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Dec 28, 2023 07:10 ET
HENLIUS: VOLUNTARY ANNOUNCEMENT - HLX42 FOR INJECTION (ANTIBODY-DRUG CONJUGATE TARGETING EGFR WITH NOVEL DNA TOPOISOMERASE I INHIBITOR) HAS BEEN GRANTED THE FAST TRACK DESIGNATION BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA)
Dec 27, 2023 04:00 ET
HENLIUS: INSIDE INFORMATION ANNOUNCEMENT - OBTAINED EU GMP CERTIFICATES
Dec 22, 2023 04:51 ET
No Data
No Data